High efficient production of Pr55gag virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A

Buonaguro, Luigi; Buonaguro, Luigi; Tornesello, Maria Lina; Mantas, D.; Beth‐Giraldo, Elke; Wagner, Ralf; Michelson, Susan; Prévost, Marie‐Christine; Wolf, Hans; Giraldo, Gaetano

doi:10.1016/s0166-3542(00)00136-4

Cited by 77 publications

(57 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We have previously reported that a candidate HIV-1 preventive vaccine, based on VLPs expressing a gp120 glycoprotein derived from an HIV-1 clade A isolate (HIV-VLP A s) [11], induces IgA and/or IgG antibody responses in sera as well as at mucosal (vaginal and intestinal) sites and CTL activity when administered by multi-regimen protocol in BALB/c mice by the intra-nasal route in the absence of adjuvants [12;16]. These results were obtained using 20 and 100 g/dose.…”

Section: Discussionmentioning

confidence: 99%

“…HIV-VLP A s, produced in insect cells and purified on a 10-60% continuous sucrose gradient [11], were administered intra-nasally in Balb/c mice following a prime-boost protocol defined "homologous" (VLP prime + VLP boost) or "heterologous" (DNA prime + VLP boost) boosting, with or without the L3 adjuvant (Table 1). Moreover, to achieve a broader neutralizing activity, the heterologous protocol can be considered also a multiclade approach, given that the DNA plasmid expresses a B-clade and the VLP an A-clade envelope.…”

Section: Induction Of Serum Antibody Response By Intra-nasal Administmentioning

confidence: 99%

“…The HIV-targeted VLPs (HIVVLPs) are based on the HIV-1 Pr55gag precursor protein property to assemble as immature, non-replicating and non-infectious VLPs with an effective induction of both arms of the immune response [7][8][9][10][11][12][13]. In particular, the enveloped HIV-VLPs developed in our laboratory present an entire gp120 molecule derived from an Ugandan HIV-1 isolate of the clade A, identified in our laboratory [11;14;15].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

DNA–VLP prime–boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity

Buonaguro

Devito

Tornesello

et al. 2007

Vaccine

View full text Add to dashboard Cite

The immune response to HIV-1 Virus-Like Particles (VLPs), presenting a clade A Ugandan gp120, has been evaluated in a mouse model by intranasal (i.n.) administration by a VLP+VLP homologous or a DNA+VLP heterologous prime-boost immunization protocol, including a HIV-1 DNA gp160/rev plasmid. Furthermore, the effect of the Eurocine lipidbased mucosal L3 adjuvant on the VLP immunogenicity has been assessed as well.The designed heterologous protocol is able to increase the env-specific humoral and cellular immune response, compared to the homologous protocol, which is to some extent increased by the administration of L3-adjuvanted VLP boosting dose. The anti-gag response is statistically increased in both homologous and heterologous protocols, particularly when the VLP boosting dose is adjuvanted.Immune sera from immunized animals exhibit >50% ex vivo neutralizing activity against heterologous A and B-clade viral isolates. An envelope B-cell epitope mapping shows an enhanced response against V3 epitopes all across the C2-V5 region in the heterologous prime-boost immunization strategy.The induction of humoral immunity at mucosal sites, which represents the main port of entry for the HIV-1 infection, is extremely relevant. In this framework, the DNA-VLP heterologous prime-boost protocol appears a promising preventive vaccine approach which can significantly benefit from specific mucosal adjuvants, as the Eurocine L3.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Induction Of Serum Antibody Response By Intra-nasal Administmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

DNA–VLP prime–boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity

Buonaguro

Devito

Tornesello

et al. 2007

Vaccine

View full text Add to dashboard Cite

show abstract

“…Virus-like particles (VLPs) have been generated in insect and mammalian cell expression systems for a number of viruses including rotaviruses, parvoviruses, human papillomavirus, and HIV by ectopic expression of subsets of their respective viral proteins (20)(21)(22)(23). These genome-free VLPs are often morphologically similar to the live virus from which they are derived and are highly immunogenic.…”

mentioning

confidence: 99%

Ebola virus-like particles protect from lethal Ebola virus infection

Warfield

Bosio

Welcher

et al. 2003

Proc. Natl. Acad. Sci. U.S.A.

229

258

View full text Add to dashboard Cite

The filovirus Ebola causes hemorrhagic fever with 70 -80% human mortality. High case-fatality rates, as well as known aerosol infectivity, make Ebola virus a potential global health threat and possible biological warfare agent. Development of an effective vaccine for use in natural outbreaks, response to biological attack, and protection of laboratory workers is a higher national priority than ever before. Coexpression of the Ebola virus glycoprotein (GP) and matrix protein (

show abstract

“…A VLP-based HIV vaccine produced in a baculovirusexpression system (Buonaguro et al, 2001) has been shown to induce specific transcriptional profiles of genes involved in the morphological and functional changes characterizing innate and early adaptive immune response both in monocyte-derived dendritic cells (MDDCs) (Aricò et al, 2005) and in PBMCs from HIV-1 sero-negative and sero-positive subjects (Buonaguro et al, 2008;Monaco et al, 2009). As for the YF-17D vaccine, HIV-VLPs induced a molecular signature including several genes implicated in innate sensing of viruses and antiviral immunity.…”

Section: Hiv Virus-like Particlesmentioning

confidence: 99%